Channing Hamlet of Objective Capital Partners to Address Important Considerations in the Sale of Your Clients Business at Southern California Institute
San Diego, CA – June 28, 2016- Objective Capital Partners is pleased to announce that Channing Hamlet, one of its Managing Directors, has been invited as a guest speaker to address important topics in the sale of a business on July 7, 2016 at the Southern California Institute (SCI) in San Diego, CA from 2:30-4 […]
Regen BioPharma, Inc. Retains Objective Capital Partners, LLC To Explore Non-Dilutive Funding Opportunities
San Diego, CA – June 7, 2016- Regen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), announced today that it has retained Objective Capital Partners, LLC as its advisor to assist the company in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide a source of non-dilutive funding. The strategies being explored include […]
Objective Capital Partners Advises Marina Biotech on Creating Greater Shareholder Value with the Addition of a Late Stage Clinical Asset
San Diego, CA and Bothell, WA – May 17, 2016 – Marina Biotech, Inc. (OTCQB:MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases, announced that the companies have executed a term sheet […]
Objective Capital Partners Closes Deal Capitalization on Tavern+Bowl
San Diego, CA- May 10, 2016 – Objective Capital Partners, a leading middle market investment bank focused on transactions for companies with enterprise values up to $500 million, is pleased to announce the equity and debt capitalization of Tavern & Bowl, LLC. (Tavern+Bowl), a leading restaurant and hospitality group. Objective Capital Partners served as the […]
Objective Capital Partners Retained by Marina Biotech to Explore Strategic Alternatives
Bothell, WA – February 18, 2016 – Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that its Board of Directors has authorized a process to explore a range of strategic alternatives to enhance shareholder value. The Company has retained Objective Capital Partners, LLC as […]
AVACEN Medical Inc. Retains Objective Capital Partners
AVACEN Explores Strategic Business Alternatives San Diego, CA – February 2, 2016 – AVACEN Medical, a privately held medical device company, announced that its Board of Directors has authorized a process to explore a range of strategic alternatives to enhance shareholder value. The Company has retained Objective Capital Partners, LLC as its exclusive advisor to […]
Objective Capital Partners Announced as Finalist For Advisor of the Year Awards
SAN DIEGO (October 20, 2015) — Objective Capital Partners is pleased to announce it has been selected as a finalist for the inaugural Advisor of the Year award. This award acknowledges local middle market mergers and acquisitions professionals who have significantly contributed to the successful sale, expansion or recapitalization of their clients’ companies. Winners will […]
Objective Capital Completes Sale of Electronic Control Systems to Albireo Energy
San Diego, CA – November 6th, 2014 – Objective Capital Partners, a leading middle market investment bank focused on transactions for privately held companies with enterprise values up to $250 million, is pleased to announce that it has completed the successful sale of Electronic Control Systems (ECS) and Green Total Solutions (GTS) to Albireo Energy, […]